证券代码：688085 证券简称：三友医疗 公告编号：2025-059 上海三友医疗器械股份有限公司 关于 2025 年度"提质增效重回报"行动方案半年度 评估报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为贯彻中央经济工作会议、中央金融工作会议精神，践行以投资者为本的 理念，落实上海证券交易所《关于开展科创板公司"提质增效重回报"专项行 动的倡议》，上海三友医疗器械股份有限公司（以下简称"公司"或"三友医 疗"）于 2025 年 5 月 24 日在上海证券交易所网站披露了《关于 2025 年度"提 质增效重回报"行动方案的公告》。根据 2025 年度行动方案，公司在 2025 年切 实履行"提质增效重回报"行动方案的具体举措，推动公司持续优化经营、规 范治理，切实履行上市公司的责任和义务，维护公司全体股东利益。公司认真 评估了 2025 年度行动方案实施效果，公司于 2025 年 8 月 22 日召开了第四届董 事会第二次会议审议通过了《关于<2025 年度"提质增效重回报"行动方案的 半年度评估报告>的议 ...

北京和上海活动报名： 第三届全球手术机器人大会 2025医疗器械研发创新论坛 在骨科高值耗材集采落地之后，整个行业都进入了"价降量升"的新常态。对厂商来说，这不是一个简单的市场扩容故事，而是生死考验：利润还能不能保住？现金 流还能不能回得来？ 大博医疗的这份2025年半年报，算是一张比较亮眼的答卷： 在价格不断下探的行业背景下，大博能同时交出 "收入快增 + 利润高弹性 + 现金流大幅改善" 的组合，确实值得细看。 一、数字背后：利润质量与现金的修复 收入和利润 上半年公司收入 12.10 亿元 ，同比增长 25.55% ；归母净利润 2.44 亿元 ，同比大涨 76.69% 。 利润增速远超收入，主要原因是： 净利率维持在 20%左右 ，在国内骨科企业中属于较高水平。 整体毛利率 71.01% ，较去年同期小幅波动。 拆分来看： 结构差异清楚地说明：公司靠关节拉动收入，但真正"养利润"的，还是创伤和微创外科。 费用与投入 营业收入 12.10 亿元 ，同比 +25.55% 归母净利润 2.44 亿元 ，同比 +76.69% 扣非净利润 2.23 亿元 ，同比 +82.64% 经营现金流净额 2.63 亿元 ...

Core Viewpoint - The company has announced its 2025 "Quality Improvement and Efficiency Enhancement" action plan, building on the achievements of the 2024 plan to optimize operations and governance while enhancing shareholder value [1]. Group 1: Business Strategy and Development - The company focuses on deepening its core business in orthopedic medical devices, emphasizing original innovation and increasing R&D investment to enhance competitiveness [1][2]. - In 2024, the company faced a significant decline in net profit, down 88% to 11.47 million yuan, primarily due to the impact of centralized procurement on spinal product sales [1]. - The company increased its R&D investment to 84.29 million yuan, a 29.24% year-on-year increase, representing 18.58% of total revenue, up 4.41 percentage points from the previous year [1]. Group 2: International Expansion - The company aims to expand its international business, leveraging its acquisition of Implanet to enhance brand recognition and market presence in developed countries [3][4]. - The JAZZ Spinal System from Implanet received FDA510(k) certification and began sales in the U.S. by the end of 2024, further enriching the company's international product line [3]. Group 3: Product Innovation and Technology - The company is advancing the development of new materials and intelligent surgical devices, focusing on integrating AI and robotics into orthopedic instruments [4][5]. - The acquisition of Waterwood Tianpeng Medical Technology Co., Ltd. aims to enhance the company's capabilities in ultrasound energy and active devices, promoting strategic synergies [6]. Group 4: Shareholder Returns and Communication - The company maintains a sustainable dividend strategy, planning to distribute a total cash dividend of 1.1671 million yuan and a capital reserve increase of 2 shares for every 10 shares held [7][8]. - The company emphasizes transparent communication with investors, utilizing various channels to ensure timely and accurate information dissemination [9][10]. Group 5: Governance and Compliance - The company adheres to strict governance standards, ensuring a well-defined structure among shareholders, the board, and management to protect shareholder interests [12][13]. - Continuous training and communication with key personnel are implemented to enhance compliance awareness and operational effectiveness [13][14].